Earnings Release • Jul 28, 2011
Earnings Release
Open in ViewerOpens in native device viewer
News Details
Corporate | 28 July 2011 07:00
Cytos Biotechnology Second Quarter Report 2011
Cytos Biotechnology AG / Key word(s): Half Year Results
28.07.2011 / 07:00
Cytos Biotechnology Ltd Second Quarter Report 2011 as of June 30, 2011
Summary of important events in Q2 2011
– Update on combined phase I/IIa study with a novel anti-interleukin-1 beta vaccine in patients with type II diabetes mellitus
– Phase IIb results with CYT003-QbG10 for the treatment of allergic rhinoconjunctivitis published in the Journal 'Clinical and Experimental Allergy'
– Constitution of the Board of Directors after the Shareholder's Meeting 2011
– Financial summary
| in CHF million | YTD* 2011 | YTD* 2010 | Q2 2011 | Q2 2010 |
| Revenue | 1.0 | 21.4 | 0.4 | 21.2 |
| Net operating costs | (10.3) | (14.4) | (4.7) | (7.5) |
| Net (loss)/income | (10.0) | 11.2 | (4.7) | 15.0 |
| 06/30/11 | 12/31/10 | |||
| Cash, cash equivalents, | 37.5 | 48.7 | ||
| financial assets | ||||
| and trade and other receivables | ||||
| Convertible bonds | 41.1 | 41.1 | ||
| (outstanding nominal value) | ||||
| Full-time equivalents (number) | 73 | 81 |
*YTD = year to date January 1 – June 30
The complete Second Quarter Report 2011 can be downloaded on Cytos Biotechnology's website under the following link:
http://www.cytos.com/userfiles/file/Cytos_Q2_2011_E.pdf
For more information please contact:
Harry Welten, MBA
Chief Financial Officer
Cytos Biotechnology Ltd
Wagistrasse 25, Postfach
CH-8952 Schlieren (Zurich)
Tel. +41 44 733 46 46
e-mail: [email protected]
End of Corporate News
28.07.2011 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.
EquityStory publishes regulatory releases, media releases on the capital market and press releases.
The EquityStory Group distributes authentic and real-time financial news for over 1’300 listed companies.
The Swiss news archive can be found at http://www.equitystory.ch/nachrichten
| Language: | English |
| Company: | Cytos Biotechnology AG |
| Wagistr. 25 | |
| 8952 Schlieren | |
| Switzerland | |
| Phone: | +41 44 733 4747 |
| Fax: | +41 44 733 4740 |
| E-mail: | [email protected] |
| Internet: | www.cytos.com |
| ISIN: | CH0011025217, CH0029060735 |
| Swiss Security Number: | – |
| Listed: | Regulierter Markt in SIX; Freiverkehr in Berlin, München, Stuttgart; Open Market in Frankfurt |
| End of News | EquityStory AG News-Service |
| - - - |
| 133436 28.07.2011 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.